Insights

Read our lastest Q&A with June Park, CEO of siRNAgen, a novel RNAi platform spun out of Korea-based Bioneer

Check out our latest Q&A with Andy Moye of Paige, a company using a cloud-based AI Platform to help drive drug discovery and treatment for cancer.

October brought numerous updates in the regulatory world for Liquid Biopsy (LBx), with additional developments in partnerships, clinical findings, and fundraising. 

In our latest Q&A, our experts spoke with Dr. Yossi Bahagon of Sweetch, an AI digital health platform.

Check out our newsletter to heard about the numerous exciting updates ranging from new company creation (Pheon Therapeutics) to major partnerships.

Our experts highlight some of the key Digital Pathology trends and themes from the 2022 Pathology Visions conference.

Check out our latest Q&A with Michael Schnall-Levin, the Chief Technology Officer of 10x Genomics.

DeciBio recently had the chance to interview Isaac Stoner of Octagon Therapeutics about their new novel targeting approaches for autoimmune diseases.

Our spatial biology experts discuss key drivers of spatial biology utilization across the research continuum. Hear the keys to getting spatial biology to the clinic from an expert spatial operator and thought leader.

Building off last year's blog, this year we recap updates in the early detection (EDx) landscape that focus on last year’s developments, identify emerging players and technologies, and highlight some geographical considerations.

Read as our experts interview with Steve Kanner, CSO at Caribou Biosciences.

DeciBio released a second edition liquid biopsy report that takes an updated and comprehensive look at the liquid biopsy (LBx) landscape.

Read our feature in the Los Angeles Business Journal, as it highlights the use of our data products to leverage the increasing entry fees needed by companies to compete in a precision medicine space.

IPT asked representatives from DeciBio, Cybin, and GORE PharmBIO for their opinions on how to help get therapeutics get to market more efficiently.

Read our September roundup to find out more about new key developments in the Next-Generation Therapeutics Space.

We sat down with a lab director to learn more about how a large reference lab approached monkeypox testing.

Liquid Biopsy (LBx) continued to develop through September, featuring ample product launches and clinical trial publications spurred on by ESMO conferences. 

While the economic slump looks as though it may continue through the final quarter of 2022, we will continue to stay abreast of emerging developments in digital health.

Read about our take on Illumina's new line of product launched at its inaugural Illumina Genomics Forum (IGF) last week.

DeciBio interviews Dusty Majumdar and Chakra Chennubhotla, CEO and CTO at SpIntellx.

Decibio interviews Dr. Chan-Young Ock of recently IPO’d digital pathology firm, Lunit.

DeciBio conducted a pulse survey with 8 U.S. oncologists to ascertain what precision oncology advancements excite them the most.

Here we explore how biomarkers are driving the immuno-oncology landscape. We dive into cutting-edge biomarker research and the challenges facing the field.

Take a look at DeciBio’s in-depth recap of strategic liquid biopsy industry activity

August was a month that had some significant new therapeutic approvals as well as company launches, in addition to several financing rounds and partnerships. Read below to find out more about these new key developments. 

Discover the new DxBook for clinical NGS oncology testing.

The accumulation of biomarker-matched clinical outcome data may imply that a new diagnostic is poised to approach the clinic.

Read as our experts interview Mark Lloyd, Executive Vice President and Founder of Inspirata, about the promise of Clinical Digital Pathology.

Our experts took a look at digital pathology partnerships more broadly, to identify the companies and collaborations that are enabling more widespread access to digital pathology tools.

Partners, Andrew Aijian and Stephane Budel, place in The Consulting Report's, "The Top 50 Healthcare Leaders in Consulting of 2022".

Our clinical diagnostics market research highlights two analyte-level trends in the infectious diseases testing market.

DeciBio Consulting joined the rankings of the TOP 100 companies in Los Angeles that are setting trends and redefining the employee experience.

This is a profile of what it is like to be a life science expert at DeciBio consulting. Check it out to learn more about having a PhD and becoming a consultant.

Read about the current Methylation Analysis Landscape projection for the year 2022 in our newest publication.

July showcased new partnerships, product launches, clinical trials, and study result updates in liquid biopsy.

Read about how understanding the market, distinct value proposition, business model, and clinical actionability of a product is essential to bridging the gap between early-stage ideas and commercialized successes.

DeciBio interviews Trey Foskett, Co-Founder and CEO of Watchmaker Genomics.

Check out our latest feature on PE insider about recent news regarding DeciBio Ventures.

ctDNA MRD and monitoring was front and center at ASCO 2022. We analyzed 19 abstracts published by leading commercial players.

July stands out for its wealth of news on company growth - read about some of the many financing rounds, acquisitions, and partnerships the next-gen space saw in the last month.

Our Q&A with co-founder and CMO at Lunaphore, Déborah Heintze, dives into the spatial biology market today and covers key details on Lunaphore’s new COMET platform.

DeciBio Ventures invested in the seed funding round for Replay. KKR & Co. Inc. and OMX Ventures led this funding round, which totaled $55 million.

With the rapid growth of liquid biopsy research, biomarkers like mtDNA, in addition to more “traditional” analytes (e.g., ctDNA, cfDNA, proteins), are being pursued.

Liquid Biopsy (LBx) in June was spearheaded by novel company partnerships and product launches as well as clinical trial launches and validation study result updates.

June was a busy month with funding rounds, study results, and manufacturing partnerships bringing a range of next gen therapeutics closer to the clinic. Happy reading!

We’ve rounded up the big headlines for you, from an Office of Inspector General data brief to exciting regulatory approvals, product launches, partnerships, and acquisitions in the digital health space.

Our life science expert highlights a key insight from this year's Precision World Medicine Conference. From digital biomarkers to liquid biopsy, read how multiomics is becoming a central part of precision medicine

DeciBio interviews Stephane Mouradian, Senior Vice President of BD & Marketing at Personalis, about the focus of the company moving forward and their highly sensitive NeXT Personal™ assay.

In this Q&A, our experts interviewed Ofer Sharon, MD, MBA, is CEO and co-founder of OncoHost, a host response profiling company in the peripheral biomarkers space.

Did short-term solutions for COVID-19 stifle long-term mRNA success?

New Podcast Episode: DeciBio interviews Jacob Becraft, the CEO and co-founder of Strand Therapeutics.

The precision oncology landscape is getting crowded, with an increasing number of players offering solutions throughout the diagnostic and treatment journey.

We had the chance to talk with Tarjei Mikkelsen PhD, CTO at ArsenalBio, a programmable cell therapy company, to get his thoughts on the cell therapy field.

The level of new announcements and innovation was one of the most impressive in recent memory and appeared non-linear compared to previous years.

This month we have seen major new trial developments and partnership changes in the cell therapy space, creative funding rounds across gene therapies, and significant manufacturing expansions for oligonucleotide therapies.

Liquid Biopsy (LBx) continued to develop through May, featuring new CE-IVD and FDA approvals, research and commercialization collaborations, and new trial launches and study results.

Liquid Biopsy (LBx) continued to develop through April, featuring new clinical and research collaborations as well as trial launches and study results.

A few of our experts talk with Daniel S. Grosu, MD, MBA, Founder, President and CEO of PetDx, a liquid biopsy company that intends to revolutionize how we detect cancer in man’s best friend — canines.

Our biomarker intelligence team summarizes critical insights on multiplex tissue analysis and digital pathology from AACR 2022. Discover key activity and key players involved in the latest clinical research.

We interviewed Omid Farokhzad about the Future of Proteomics: Seer’s Origins & the Proteograph’s Commercial Launch.

From ViVE 2022 to exciting regulatory approvals, product launches, partnerships, and acquisitions for the digital health space, Q1 2022 is off to an eventful start.

Liquid Biopsy (LBx) continues to develop with each month, featuring more clinical trial updates and platform launches as well as new LBx approvals worldwide.

The field of single cell continues to evolve at a remarkable pace. We caught up with CEO and co-founder Sean Mackay to hear more about recent developments at the company.

Our research tools consulting experts discuss the exciting spatial omics market with Michael Schnall-Levin, specifically how novel technologies are enabling high-plex spatial imaging for translational and discovery research.

Our research tools consulting experts discuss the exciting spatial omics market with Niro Ramachandran.

Liquid Biopsy (LBx) continues to be of relevance now and in the future, with more clinical trial updates and launches taking place every month, as well as with new LBx approvals worldwide.

DeciBio Consulting was again named a top consulting firm to work for in North America. Vault.com awarded DeciBio the #30 ranking on its 2022 edition of its signature list, the Vault Consulting 50. DeciBio also advanced to #4 on Vault’s 2022 Best Boutique Consulting Firms list. DeciBio is one of the youngest firms on either list.

Liquid Biopsy (LBx) companies push forward on clinical trial inclusion for greater real world validation, cancer indication expansion for existing assays, and regulatory approval in the US and Europe.

Our research tools consulting experts discuss the clinical transition of spatial omics technologies.

Q4 2021 was an exciting quarter for #digitalhealth with a focus on new product launches, new players, acquisitions, and regulatory updates.

End-of-the-year 2021 poised the Liquid Biopsy industry to have an explosive new year in 2022 with multiple medicare coverage designations, product launches, clinical trial progression, and promising funding rounds.

DeciBio Consulting, LLC, has tapped Miguel Edwards, Ph.D., as Partner.

Discover the top three differentiators that set DeciBio consulting apart from other consulting firms

With record investment going into next-generation therapies, we take stock of the field and make our predictions for what 2022 will bring for gene and cell therapies.

DeciBio Ventures aims to invest in start-ups across both tools and therapeutics

This article discusses how Spherical Nucleic Acids are differentiated and the current commercial pipeline.

November 2021 was packed full of promising developments across the Liquid Biopsy (LBx) industry with major regulatory developments, clinical trials announcements, new product launches and performance updates, and much more.

This review highlights meta-analysis of all MTA abstracts identified at the SITC 2021 annual meeting.

We speak with Jessica Owens about what makes for a successful life science venture, how digital biomarkers start to play into the precision medicine landscape, and more.

DeciBio Consulting upholds a strong company culture and encourages a healthy work life balance. This video highlights what it is like to be a "DeciBion".

September and October 2021 were packed full of promising developments across the Liquid Biopsy (LBx) industry with new product launches, clinical trials, regulatory developments, and much more.

DeciBio Consulting, the leading precision medicine strategy consulting firm, will become carbon neutral in 2022. To help accomplish this carbon neutral goal, DeciBio is partnering with My Forest Armenia (MFA), a nonprofit organization that plants trees and funds scientific research.

We caught up with Anjali Pradhan, the Vice President of Product Management at Mission Bio to hear more about recent developments at the company.

Our research tools consulting experts discuss the exciting spatial omics market with Garry Nolan.

Learn about what distinguishes DeciBio from various members at the firm.

Oncology has driven the adoption of precision medicine, which in turn has resulted in dramatic improvements for patient outcomes in some indications.

While R&D efforts to date have made significant strides in improving diagnostic and therapeutic options for infertility, there is still a massive unmet need to personalize diagnosis and treatment options.

2020 and 2021 have proven to be incredibly exciting and pivotal times for ctDNA MRD and monitoring: multiple companies noted intentions to enter the MRD / monitoring space

Akoya Biosciences has emerged as a key player in the spatial biology market, and we had the opportunity to speak with their CEO - Brian McKelligon.

We had the opportunity to speak with Suchismita Acharya about her experiences starting AyuVis Research. AyuVis Research is a preclinical stage pharmaceutical company in Fort Worth, TX

We had the opportunity to speak with Stephanie Campbell about her experiences as a co-founder of The Artemis Fund

The range of technologies that enable multiplex tissue analysis (MTA) and digital pathology (DigPath) are rapidly growing and entering the clinical research space.

With renewed interest in disparate applications and the subsequent flood of newcomers to mRNA asset development, the focus on quality and experience with regard to mRNA is more important than ever.

We had the opportunity to speak with Michelle Dipp about her experiences as a co-founder of Biospring Partners

We’ll talk about how he envisions humanity preparing to move beyond our home on earth in the next few centuries, and how that relates to precision medicine over the next few years.

Partner Stephane Budel believes precision medicine has the potential to drastically improve health care outcomes

Companion diagnostic (CDx) tests are a foundational tool in precision medicine, helping ensure only the right patients receive the right therapies.

After nearly a decade of disappointment after disappointment, IBM announced earlier this year that they are looking to sell Watson Health.

We had the opportunity to speak with Terry Lo and George Emanuel to discuss the announcement, MERSCOPE, and the spatial omics industry overall

We had the opportunity to sit down and discuss Seer’s technology and the proteomics market with Omead Ostadan